Novavax, Inc. NVAX shares are trading higher by 9.8% at $230.25 Monday morning after the company announced positive Phase 3 trial results for its COVID-19 vaccine.
According to Novavax, its COVID-19 vaccine has 93% efficacy against predominantly circulating variants of concern and variants of interest and 91% efficacy in high-risk populations.
Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
